Research programme: hexokinase II inhibitors - Calithera Biosciences/vTv Therapeutics

Drug Profile

Research programme: hexokinase II inhibitors - Calithera Biosciences/vTv Therapeutics

Latest Information Update: 06 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics LLC
  • Class Small molecules
  • Mechanism of Action Glycolysis inhibitors; Hexokinase inhibitors; Small interfering RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Mar 2016 Calithera Biosciences has patents pending directed to compositions of matter for hexokinase II inhibitors and therapeutic methods of using the compounds in USA (Calithera Biosciences, 10-K, March 2016)
  • 20 Mar 2015 Preclinical trials in Cancer in USA (unspecified route)
  • 05 Mar 2015 Hexokinase II inhibitors licensed to Calithera Biosciences worldwide for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top